CLINICAL TRIALS PROFILE FOR NALBUPHINE
✉ Email this page to a colleague
All Clinical Trials for NALBUPHINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00155233 ↗ | Interaction Between Nalbuphine and Morphine in PCA | Unknown status | National Taiwan University Hospital | Phase 4 | 2005-01-01 | 1. Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist 2. This study was designed to investigate the interaction between nalbuphine and morphine |
| NCT00200564 ↗ | Ketamine and Postoperative Analgesia in Children | Unknown status | Nantes University Hospital | Phase 4 | 2004-02-01 | The benefit of small doses of ketamine has been demonstrated for postoperative analgesia in adults but remains unproved in children. The investigators' purpose is to evaluate the effects of continuous intravenous small doses of ketamine versus placebo to improve the quality of postoperative analgesia in children (6 months to 6 years of age). Caudal anesthesia is performed for intraoperative analgesia and all children receive paracetamol, a non-steroidal anti-inflammatory and continuous intravenous nalbuphine. |
| NCT00323154 ↗ | Nalbuphine for the Treatment of Opioid Induced Pruritus in Children | Completed | University of British Columbia | Phase 3 | 2004-03-01 | Itching is a frequent and disturbing side effect of the use of pain medication such as morphine. In the post-operative period, it can be more distressing to pediatric patients than their pain. The current first line treatment, an antihistamine (Benadryl), has a low efficacy. This treatment causes sleepiness and may be dangerous when used in combination with other drugs. Nalbuphine has analgesic properties similar to morphine as well as the ability to reverse some morphine-induced side effects, such as respiratory depression and itching. Nalbuphine has been used effectively for patients undergoing Caesarean sections. However, the effectiveness of nalbuphine in the pediatric population has not been investigated. We want to determine the efficacy of nalbuphine in the treatment of itching after morphine for postoperative pain relief. We will use a novel method to measure the effect of the treatment using an intensity scale before and after the drug, to determine the intensity difference. |
| NCT00499746 ↗ | The Discriminative Effects of Tramadol in Humans | Completed | National Institute on Drug Abuse (NIDA) | Phase 1/Phase 2 | 2007-11-01 | This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram. It has effects similar to morphine, and it may also have effects similar to other drugs like stimulants. The doses of tramadol used in this study are higher than those generally used for the treatment of pain. To be in this study a participant must be a user of opioids (drugs like heroin) and stimulants (drugs like cocaine), but cannot be addicted to either. The person must be between 21-55 years old, and generally healthy. Up to 12 people will take part in this study. |
| NCT00707824 ↗ | Epidural Nalbuphine for Postcesarean Epidural Morphine Induced Pruritus | Completed | Mahidol University | Phase 4 | 2000-06-01 | Can epidural nalbuphine reduce incidence or severity of epidural morphine induced pruritus in patient undergoing cesarean section? |
| NCT00716807 ↗ | Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain | Terminated | University of California, San Francisco | N/A | 2008-01-01 | Patients with chronic masticatory muscle pain (i.e., pain greater than three months) or patients with burning mouth syndrome participate in this study. The aim of the study is to compare the pain killing effectiveness of nalbuphine, a narcotic pain killer, administered with either placebo or naloxone, a drug used to treat opiate overdose. A second goal is to determine if there are sex differences in these two drug regimens. Drugs will be administered with single-use intranasal spray devices. All participants will receive two sprays (one spray per nostril). One of the two sprays will be nalbuphine (5 mg). The other spray will be naloxone in half the participants and placebo in the other half. |
| NCT00874172 ↗ | Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy | Completed | Assistance Publique - Hôpitaux de Paris | N/A | 2009-10-01 | Quality of life of adult patients with sickle cell disease is deeply impaired by severe adverse medical events that inadvertently occur throughout their time life. Indeed, patients not presenting a life threatening condition often present to the emergency department with sickle cell disease crisis related pain. Currently, the effectiveness of specific analgesic strategies for treating sickle cell disease crisis related pain are mostly based on acetaminophen and opioid derivates combination along with oxygen delivery. Those strategies are effective but may last up to half an hour to obtain pain relief. This delay mostly depends on the availability of venous access and on individual patient response to treatment. Nitrous oxide is a volatile efficient analgesic therapy that has been repeatedly shown to allow rapid analgesia in the emergency department setting. The investigators hypothesise that a new analgesic strategy (rapid optimized analgesic strategy) including nitrous oxide and nefopam would be as safe and more rapidly effective than current analgesic strategy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NALBUPHINE
Condition Name
Clinical Trial Locations for NALBUPHINE
Trials by Country
Clinical Trial Progress for NALBUPHINE
Clinical Trial Phase
Clinical Trial Sponsors for NALBUPHINE
Sponsor Name
